IP Verse

Gilead Sciences competitive analysis

Loading summary...

Latest oppositions filed by Gilead Sciences

Explore patent oppositions filed by Gilead Sciences against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Nov 6, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3854403
Use Of Substituted Aminopropionate Compounds In Treatment Of Sars-Cov-2 InfectionACADEMY OF MILITARY MEDICAL SCIENCESJun 18, 2025
EP2399588
Nucleoside Derivatives As Inhibitors Of Rna-Dependent Rna Viral PolymeraseIONIS PHARMACEUTICALSJan 7, 2021
EP3284520
Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory ActivitySHIONOGIFeb 4, 2020
EP2955190
Chemical CompoundsNUCANADec 17, 2018
EP3045206
Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory ActivitySHIONOGIDec 6, 2018

Latest patents of Gilead Sciences opposed by its competitors

Explore Gilead Sciences's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 6, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3321270
Dec 4, 2024Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5] Pyrazino [2, 1-B] Oxazepin-8-Olate5
EP4233846
Dec 4, 2024Pharmaceutical Formulations3
EP3595667
Dec 20, 2023Pharmaceutical Compositions Comprising A Jak Inhibitor3
EP2655623
Aug 30, 2023Non-Coding Immunomodulatory Dna Construct1
EP4070788
Mar 22, 2023Pharmaceutical Formulations1
EP4070787
Mar 1, 2023Pharmaceutical Formulations1
EP2709613
Aug 12, 2020Methods For Treating Hcv1
EP3150586
Jan 8, 2020Modulators Of Pharmacokinetic Properties Of Therapeutics3
EP3346995
Aug 28, 2019Therapeutic Compositions For Treatment Of Human Immunodeficiency Virus3
EP3157932
Jan 10, 2018Sodium (2R, 5S, 13Ar) -7, 9-Dioxo-10- ( (2,4,6-Trifluorobenzyl) Carbamoyl) -2, 3, 4, 5, 7, 9, 13, 13A-Octahydro-2, 5-Methanopyrido [1',2' : 4.5]Pyrazino [2, 1-B]Oxazepin-8-Olate1

Latest PTAB cases involving Gilead Sciences

Discover the latest PTAB cases involving Gilead Sciences, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 5, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Gilead Sciences

IPR2025-00033Oct 28, 2024CIPLAGILEAD SCIENCESInstitution Denied
PGR2023-00046Aug 7, 2023ATEA PHARMACEUTICALSGILEAD SCIENCESInstitution Denied
IPR2019-01455Aug 23, 2019GILEAD SCIENCESUNITED STATES OF AMERICAInstitution Denied
IPR2019-01456Aug 23, 2019GILEAD SCIENCESUNITED STATES OF AMERICAInstitution Denied
IPR2019-01453Aug 21, 2019GILEAD SCIENCESUNITED STATES OF AMERICAInstitution Denied
IPR2019-01454Aug 21, 2019GILEAD SCIENCESUNITED STATES OF AMERICAInstitution Denied
IPR2017-02005Aug 29, 2017GILEAD SCIENCESREGENTS OF THE UNIVERSITY OF MINNESOTAInstitution Denied
IPR2017-02004Aug 28, 2017GILEAD SCIENCESREGENTS OF THE UNIVERSITY OF MINNESOTAInstitution Denied
IPR2017-01753Jul 7, 2017GILEAD SCIENCESREGENTS OF THE UNIVERSITY OF MINNESOTAInstitution Denied
IPR2017-01712Jun 30, 2017GILEAD SCIENCESREGENTS OF THE UNIVERSITY OF MINNESOTAFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Gilead Sciences with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 6, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
GILEAD SCIENCES53186
COOKE27 - - -
MYLAN PHARMACEUTICALS - - 94 -
REGENTS OF THE UNIVERSITY OF MINNESOTA - 5 - 11